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Background: Head and neck cancer is a major health problem. 
Recent studies on the pathobiology of oral squamous cell 
carcinoma (OSCC) have led to the discovery of a small 
population of cancer cells with a consistent behavior with the 
features of cancer stem cells (CSCs).  CSCs are required and 
responsible for initiation, maintenance and recurrence of disease. 
Molecular markers are commonly used for the identification of 
CSCs. CD44 is the most reported CSC marker in OSCC. The 
aim of the study was to evaluate and correlate the expression of 
CD44 in different histopathological grades of OSCC, as well as 
to assess the diagnostic and prognostic value of soluble CD44 
(CD44sol) in peripheral blood of patients. 
Materials and methods: Fifteen patients with OSCC were 
included; biopsies were histologically evaluated using 
haematoxylin and eosin. Serial sections were 
immunohistochemically stained by monoclonal antibody to 
CD44. The intensity of immunostaining of CD44 was calculated. 
Enzyme-linked immunosorbent assay (ELISA) method was used 
to determine the concentration of CD44sol in the blood serum.  
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Introduction 
 
Head and neck cancer is a major health problem throughout the world.(1) 
Head and neck squamous cell carcinoma (HNSCC) is one of the most common 
malignancy in humans and one of the most common malignant tumors of the oral 
and maxillofacial regions. (2) In 2008; 263,900 new cases of head and neck cancer 
were diagnosed and 128,000 deaths related to this malignancy have occurred 
worldwide.(1)  
Estimation reveals that 11 out of every 100,000 adults diagnosed every year 
with oral cancer. (3) The standard of care for patients with OSCC includes 
platinum-based chemotherapeutic drugs, surgery and radiotherapy. (2) Surgical 
treatment and frequent local recurrences significantly reduce patient’s quality of 
life.(4)  
 
Oral Squamous Cell Carcinoma 
 
Cancer that forms in tissues of the oral cavity or the oropharynx is referred 
as the oral cancer. Among all oral mucosal origin cancers, about 90% are 
squamous cell carcinoma (SCC).(5)  
Oral cancer holds the eighth position in the cancer incidence ranking 
worldwide, with epidemiologic variations between different geographic regions. (It 
is the third most common malignancy in south-east Asia.) (2, 6) 
Results: All grades of OSCC showed membranous 
immunosignaling of CD44. The well, moderately and poorly 
differentiated OSCC cases showed weak, moderate and intense 
positive membranous immunosignaling of CD44 respectively. 
CD44sol levels were significantly higher in OSCC patients than 
they were in control groups. Soluble CD44 serum levels were 
significantly higher in poorly differentiated than they were in 
moderately and well differentiated. 
Conclusion: CSCs detection in fixed human tissue and CD44sol 
detection in peripheral blood using ELISA seemed to be a 
promising method and may have a diagnostic and prognostic 
value in management of OSCC. 
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Oral cancer is twofold more prevalent in men than in women, due to increased 
alcohol consumption and tobacco habits ranging from sixty to seventy years of 
age.(7)  
The tongue is the most common location; how-ever, it can also affect the lip 
mucosa, buccal mucosa, gingiva, floor of the mouth and palate. (8)  
Despite advances in therapy, survival rates have remained static and mortality 
from OSCC remains high. It is therefore essential to develop a better 
understanding of the biology of this disease to develop more effective 
therapies.(9)  
Studies on the pathobiology of OSCC have led to the discovery of a specific 
limited population of cancer cells that are highly tumorigenic, capable of self-
renewal and behave as tumor progenitor cells.(9, 10) Such behavior is consistent 
with the features of cancer stem cells (CSCs).(11) 
 
Stem Cells 
 
Stem cells are pluripotent cells with the capacity for self-renewal and 
differentiation into various types of adult cells.(12) Ever since their discovery in 
1960s, stem cells have been "the secret of life" itself.(13) Stem cells are roughly 
categorized as embryonic stem cells (ESCs), mesenchymal stem cells (MSCs) and 
induced pluripotent stem cells (iPSCs).(14)  
Embryonic stem cells are derived from the inner cell mass of preimplantation 
embryos and demonstrate excellent pluripotency.(15) Mesenchymal stem cells are 
multipotent stromal cells that have been isolated from both adult and fetal 
tissues and are defined as adherent fibroblast-like cells.(16)  
The more recently introduced iPSCs show enormous promise for disease 
modeling and regenerative medicine. This is because their pluripotency is similar 
to that of ESCs and their utilization is without ethical controversy.(14, 17)  
A better understanding of the mechanisms involved in tumor biology will 
pave the way for prevention and early detection of the tumors. CSCs and normal 
stem cells possess similar characteristics such as: 
1. Self-renewal capacity 
2. Differentiation capacity to mature progeny 
3. Ability to survive for a long time 
4. Resistance to damaging agents 
5. Anchorage, independent growth and metastasizing capacity 
6. Active telomerase expression (telomere ‘‘shortening’’ leads to chromosomal 
instability) 
7. Active membrane transporter activity (responsible for chemotherapy 
resistance) 
 
Cancer Stem Cells 
 
According to the American Association for Cancer Research (AACR) 
workshop on CSCs in 2006,(18) neoplastic stem cells were defined as; cells within 
the tumor that are capable of self-renewal as well as of differentiation into 
various types of cells of the same line, ensuring phenotypic heterogenicity of the 
tumor  and serving as progenitor cancer cells. 
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History of the Cancer Stem Cell 
 
The concept of CSC first originated in 1855, when the German pathologist 
Rudolf Virchow (19) proposed that cancers arise from the activation of dormant 
embryonic cell remnants. The idea that cancer can originate from a small 
population of cells with stem cell properties was proposed about 150 years ago by 
the Italian surgeon Francesco Durante in 1874.(20) 
Regarding solid tumors, in 2003 Al-Hajj et al (21) first identified and isolated 
a population of CSCs from breast cancer, showing that only a subset of them, 
which exhibited expression of the surface markers CD44+/ CD24– or low  had 
tumorigenic capacity. They experimentally confirmed the ability of transplanted 
stem cells to restore a phenotypically heterogeneous structure of a tumor.  
Cancer stem cells were found in several other cancers, including liver and 
melanoma.(11) Also, populations of CSCs were identified and isolated in other 
solid tumors as; brain(22), prostate(23), colorec¬tal(24), pancreatic(25) and lung 
cancers.(26) 
Research studies are dominated by the hypothesis that there is a small 
population of cells within the main tumor mass containing stem cell features.(9, 
27)  CSCs are required and responsible not only for initiation, but also for 
maintenance and recurrence of disease.(9) 
 
Origin of Cancer Stem Cells 
 
Two main hypotheses exist regarding the origin of CSC, they either 
originates from a somatic tissue cell that undergoes genetic mutations, becomes 
cancerous and acquires stem cell characteristics, or from embryonic or adult stem 
cells as a result of genetic mutations.(28) 
 
Properties of Cancer Stem Cells 
 
The intrinsic properties of CSCs, resides in their ability to duplicate, 
differentiate and control homeostasis.(20) CSCs possess five major potentials 
which render them ‘immortal’: 1) self-renewal capacity, 2) high proliferation 
ability, 3) drug resistance, 4) high migration capacity and 5) differentiation into 
multiple mature progeny.(29) 
 
Niches 
 
Cell ‘niche’ is formed of a heterogeneous group of cells (fibroblasts and 
endothelial cells) and cellular matrix.(30) It has been proven that 
microenvironment plays an undeniable role in the biology and development of 
CSCs.(31) It may also play a pivotal role in tumor response to therapeutics.(30) 
 
Uses of Cancer Stem Cells in Treatment 
 
It is believed that existence of CSCs may be the reason for the lack of 
effectiveness of conventional treatment methods.(32) In OSCC, where the first 
Open  Science  Journal  
Research Article 	  
Open  Science  Journal  -­‐  August  2017     	   5  
and fundamental method of treatment involves surgical removal of the tumor, 
CSCs might have already metastasized at the time of surgery. They are probably 
responsible for tumor recurrence.(33) 
Cancer stem cells show more resistance to chemo- and radiotherapy than 
non-stem cells. (34) Targeted elimination of these cells was considered to provide 
a new framework for head and neck cancer treatment.(35)  
 
Role of Cancer Stem Cell in Progression and Metastasis 
 
Cancer stem cells play a role not only in the creation of cancer, but also in its 
evolution, metastasis and recurrence. CSCs have an important role in cancer 
therapy and the resistance towards chemotherapeutic agents.(29, 36)  
 
Epithelial-Mesenchymal Transition and Cancer Stem Cells 
 
Epithelial-mesenchymal transition allows epithelial cell to assume a 
mesenchymal cell characteristics, which possesses enhanced motility and 
invasiveness (37) CSCs are responsible of metastasis and invasion .(38) 
EMT is involved in the acquisition of CSC properties. Eventually, epithelial 
cells lose their cell attachment and migrate elsewhere.(39) Loss of cell polarity is 
a critical step in EMT.(40) Also loss of E-cadherin appears to be correlated with 
tumor progression and a crucial step in the progression from a benign to a 
malignant tumour. (41) These facts supports the fact that EMT leads to 
recurrence, metastasis and poor clinical prognosis.(11)  
 
Methods for CSCs Identification and Isolation 
 
Surface Antigens 
As CSCs constitute a small percentage (less than 10%) of cancer cells, they 
may be extremely challenging to characterize.(33) Molecular markers are one of 
the most commonly used strategies for the identification of CSCs. (11) CSCs 
markers includes CD34, CD133, CD24, CD29, CD31 and CD44.(42, 43) The 
identification and characterization of the CSCs may aid in tailoring efficacious 
targeted therapies and minimizing recurrences.(9) it will also aid patient 
characterization according to their tumor aggressiveness and prognosis. (44) 
The CSC hypothesis has also been coined for OSCC; among the cell surface 
markers reported as CSC markers in OSCC are; CD44, CD133 and CD24.(45-47) 
Among them, CD44 is the most reported CSC marker in OSCC.(48-50) 
 
Markers in Solid Tumors 
 
CD44 
CD44 is an integral cell membrane glycoprotein, (51) it is involved in cell 
migration and adhesion. CD44 is believed to be a key marker for identification of 
CSCs in SCC.(52) CD44 binds to several ligands; hyaluronic acid (HA) is the 
most prominent among them.(53) HA is a linear polymer of repeating 
disaccharide. CD44 has tens of isoforms, the most common one is standard CD44 
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(CD44st). Hyaluronic acid is a major constituent of the extracellular matrix and 
is believed to create a low resistance matrix, allowing enhanced cell motility. (54) 
CD44 is of particular interest because it seems to be a relatively early marker 
of malignancy.(55) CD44 isoforms are expressed in variable degrees in normal and 
tumor cells, which prove that it exhibits a normal cellular function. (56) 
 
Expression of CD44 in Non Tumor Tissue  
CD44 is widely expressed on many types of epithelium and mesenchymal 
elements. (57) In normal upper aerodigestive tract epithelium, CD44 is expressed 
at the basal cell layer. However, in dysplastic epithelium and invasive OSCC, its 
expression may involve all layers of the epithelium in most of the cases.(58, 59) 
 
In OSCC 
The existence of CSCs in OSCC was first described in 2007 by Prince et al 
(9) who used CD44 to isolate CSCs. These cells were capable of tumor formation 
when implanted in immunosuppressed mice. 
 
Soluble CD44  
Considering the implication of CD44 in the activation of cell replication, its 
antiapoptotic activity and its potential as a marker of CSCs in epithelial 
tumors,(60) it was decided to study the role of soluble CD44 (CD44sol) in head 
and neck tumors by focusing on the identification of its soluble fraction in the 
peripheral blood in OSCC patients.  
In pathological conditions such as cancer, the extracytoplasmic domain of the 
CD44 receptor detaches and is released into biological fluids as D44sol).(48) The 
determination CD44sol could be a simple, noninvasive tool in cancer screening 
and in treatment follow up.(61) A drop is the level of CD44sol was observed 
following tumour resection, which assumed that,  most likely it resulted from 
tumor cells.(62) Soluble CD44 appears to be a possible screening marker routine 
screening owing to early diagnosis of head and neck tumors.(63)  
The Enzyme-linked immunosorbent assay (ELISA) system is cited as the 
most sensitive, well-established and widely available protein-based testing 
platform for the detection of cancer in body fluids.(64)  
 
Soluble CD44 in Non Cancer and cancer Patients 
CD44sol level in the serum of normal individuals was (2.7 ± 1.1 IU/ml). In 
HNSCC, a study showed that CD44sol was elevated in oral rinses of patients 
with disease invading mucosa and not elevated in any of the normal controls. 
Kawano et al (65) found that post treatment CD44sol level was significantly 
lower than the pretreatment levels of HNSCC patients. 
In 2007 Franzmann et al (55) concluded that CD44sol was elevated in the 
majority of HNSCC cases and distinguished cancer from benign disease with high 
specificity. In 2012 Franzmann et al (66) found that high levels of CD44sol was 
significantly associated with HNSCC. Concluding that oral rinse levels of CD44sol 
and protein appear to hold promise for detection of HNSCC. 
Due to the implication of CD44 in the activation of cell replication, its 
antiapoptotic activity and its potential as a marker of CSCs in epithelial tumors, 
as well as the role of CD44sol in HNSCC; the present study was conducted to 
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evaluate the expression of CD44 in tumor tissue and its soluble fraction in the 
peripheral blood in OSCC patients.  
The aim of the present study was to evaluate and correlate the expression of 
CD44 in different histopathological grades of OSCC, as well as to assess the 
diagnostic and prognostic value of CD44sol in peripheral blood of cancer and non 
cancer patients. 
 
 
Material and Methods 
 
I. Peripheral Blood Sample 
Fifteen peripheral blood samples were from fifteen patients clinically 
diagnosed with OSCC were selected from the Cranio-Maxillofacial and Plastic 
Surgery Department at the Faculty of Dentistry, Alexandria University. Three 
peripheral blood samples were from squamous cell papilloma patients and three 
peripheral blood samples from three healthy individuals serving as negative 
control. Written informed consents were taken from all the patients. 
 
II. Tumor Tissue Sample 
Fifteen surgical specimens were taken from the same fifteen selected patients. 
Three surgical specimens were taken from squamous cell papilloma, serving as 
negative control. Written informed consents were taken from all the patients. 
 
III. Methods  
Biopsies were taken from the tumor tissue and fixed in 10% neutral buffered 
formalin, processed and embedded in paraffin wax using the conventional 
procedures. Serial sections of 3-4 µm thick were placed on glass slides and stained 
using hematoxylin and eosin (H&E) for routine histopathological examination. 
This was followed by histological grading of the tumor into well, moderate and 
poorly differentiated SCC. 
The serum was removed from the clot or red blood cells as soon as possible 
after clotting and separation. Samples were stored frozen at -20°C. The ELISA 
plate and the standard curves whole kit were stored at 2°C. 
 
IV. Immunohistochemical interpretation 
Immunohistochemical marker of mouse monoclonal antibody MGMT Ab-1 
(Clone MT 3.1). Cat. #MS-470-R7 (7.0ml) (Thermo Fisher Scientific, CA, USA) 
was used. Strept-Avidin Biotin-peroxiadase complex method (LSAB) was used 
(Lab vision corporation). Serial sections 4-5 µm thick were taken from the 
previously used paraffin blocks for H&E. The slide will be mounted on poly-L-
lysine coated glass slides. Two sections will be obtained for the positive test slides 
and third one for the negative control by omitting the primary antibody. The 
tissue sections were deparaffinized in xylene, rehydrated in graded ethanol and 
incubated in 0.3% hydrogen peroxide solution to block the endogenous 
peroxidase. The specimens were washed with an appropriately characterized, 
diluted and were incubated with the primary antibody of MGMT. Exposure to 
biotinylated link antibody and labeled streptavidin-biotinperoxidase complex was 
done to bind the primary antibody. Staining was completed by incubation in 
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substratechromogen solution and hematoxylin counter stain. Immuno-expression 
of MGMT will be evaluated by using image analyzer to evaluate both mean area 
percent and mean optical density. The results were recorded and statistically 
analyzed using one-way analysis of ANOVA. 
 
V. ELISA interpretation 
Human CD44 ELISA kit, for the quantitative level of CD44 (standard and 
variant isoforms) in the sample was used. ∗ Preparation was done according to 
the manufacturer instructions. 
The difference in the concentration of circulating human CD44 in OSCC 
samples in different grades were estimated using the one-way analysis of 
ANOVA, and estimated in tumours exhibiting or lacking invasion into the 
surrounding structures using student (t) test. 
 
 
Results 
 
I. Clinical results 
In the present study, a total of fifteen patients with OSCC were included. 
The patients’ age ranged between 52 and 71. The mean age was found to be (61.8 
± 6.3 years). Ten patients (66.7%) were males and five patients (33.3%) were 
females.  
 
II. Histopathological Results  
The microscopical examination revealed that five cases (33.3%) were of the 
well differentiated type, eight cases (53.3%) were moderately differentiated OSCC 
and two cases (13.3 %) were of the poor differentiated type. 
 
III. Immunohistochemical Results  
All oral squamous cell papilloma cases (n=3) showed positive 
immunoreactivity for CD44 in certain areas. The immunoreaction appeared as 
brownish membranous reaction in the basal and suprabasal layers.  
All grades of OSCC cases showed membranous immunosignaling of CD44. 
The nuclei, cytoplasm and keratin were free from any reaction in all the samples. 
The well differentiated OSCC cases showed weak positive membranous 
immunosignaling of CD44 in the peripheral epithelial cells forming the epithelial 
pearls and nests (Fig 1). The moderately differentiated OSCC cases demonstrated 
moderate positive membranous immunoreaction of CD44 (Fig 2). In the poorly 
differentiated type of OSCC, intense CD44 immunopositivity was detected in the 
malignant epithelial cells. It showed the highest number and greatest intensity of 
immunopositive cells (Fig 3). 
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
Fig 1: a) Well differentiated OSCC revealing weak membranous 
immunoreactivity of CD44 in the peripheral epithelial cells of the keratin pearl. 
Notice that the keratin and the central cells are immunonegative (Immuno stain 
of CD44 x 100). b) Higher magnification of Well differentiated OSCC (Immuno 
stain of CD44 x 200). 
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c) 
Fig 2. a) Moderately differentiated OSCC showing moderate positive 
membranous immunoreactivity (moderate intensity) of CD44 in almost all 
anaplastic cells forming malignant cell nests (Immuno stain of CD44x 100). b) 
Moderately differentiated OSCC showing evident moderate positive membranous 
immunoreactivity of CD44 mainly in the peripheral malignant cells of the nest 
and some of the central cells. Most of the central cells are immunonegative 
(Immuno stain of CD44 x 200). c) Moderately differentiated OSCC showing 
moderate positive membranous reaction of CD44 of all the malignant epithelial 
cells forming the cell nest, notice the desmosomes. The nucleus and cytoplasm are 
immunonegative (Immuno stain of CD44 x 1000). 
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
Fig 3: a) Poorly differentiated OSCC showing intense positive membranous 
reaction of CD44 in the anaplastic cells forming the sheets of malignant epithelial 
cells. Nucleus and cytoplasm are immunonegative (Immuno stain of CD44 x 200). 
b) Poorly differentiated OSCC revealing intense positive membranous positive 
reaction of CD44 in the anaplastic malignant epithelial cells forming the sheets. It 
also shows abnormal mitosis (arrow) (Immuno stain of CD44 x 400). 
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IV. CD44 Expression in Correlation with Histological Grade of OSCC 
Both mean area percent and mean optical density of CD44 expression in all 
OSCC cases were correlated with their histological grade using the image 
analyzer computer system. 
The difference in mean CD44 area present and optical density between the 
well, moderately and poorly differentiated groups using F-test (ANOVA) revealed 
significantly higher difference at (p<0.001).  
 
V. ELISA Results 
CD44sol levels were significantly higher in OSCC patients than they were in 
patients with benign epithelial tumor and in healthy individuals (18.66 ± 3.52 
IU/ml, 6.5 ± 1.32 IU/ml and 2.8 ± 0.53 IU/ml) respectively at (p<0.001). 
Soluble CD44 serum levels were significantly higher in poorly differentiated than 
they were in moderately and well differentiated (26.07 ± 2.96 vs. 18.55 ± 1.33 vs. 
15.88 ± 1 IU/ml) respectively. In moderately differentiated CD44sol serum levels 
were significantly higher than they were in well differentiated. CD44sol serum 
levels were significantly higher in OSCC patients exhibiting invasion into the 
surrounding structures compared to others lacking invasion at (p<0.001). 
 
 
Discussion 
 
The present study was carried out on patients with OSCC. The clinical data 
in the present work revealed that the age range of the OSCC patients with a 
mean age 61.8 ± 6.3 years. This finding was in accordance with most studies.  (8) 
It has been accepted for a long time that carcinomas are associated with old age. 
(67) This may be due to the longer duration of exposure to environmental 
carcinogens, as well as the cumulative effect of these carcinogens.(68)  
The current study results were in contrast to those of Sharma et al, (69)  
who stated that the incidence of OSCC was increasing in younger individuals; 
this may be due to the increase intensity of bad habits engagement.  
In the present study, males (66.6%) were more commonly affected than 
females (33.3%). This was in accordance to many studies that supported the fact 
that oral cancer is more common in males than in females.(70) The reported 
gender differences were attributed to heavier indulgence in risk habits by men 
and exposure to sunlight (for lip cancer) as a part of outdoor occupations.(67) 
However, those results were in contrast to those found by Patel et al (71) 
who found that there was an increasing incidence of OSCC in females especially 
young ones. The increasing incidence of females affected with SCC may be 
attributed to the increase in the use of tobacco and alcohol drinking in females 
nowadays,(72) HPV (73) and increased longevity of females.(68) 
The clinical distribution of OSCC in the current study revealed that the 
lateral side of the tongue was the most prevalent site of occurrence for OSCC 
(46.7%) followed by the alveolar mucosa (26.7%). These results were in 
consistence with many investigators who reported that the tongue was the most 
common site for OSCC. (8, 74)  
The results were in contrast to those found by Effiom et al (75) who found 
that the mandibular alveolar ridge followed by the tongue were the most common 
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sites. They attributed that to the tendency of the carcinogens in tobacco, alcohol 
or dissolved food to pool in gravity dependent areas of the mouth.  
CD44 has been selected as a marker for identifying CSCs in SCC. It was 
usually accepted as a poor prognosis marker.(76) A small subpopulation of 
positive cells (CSCs) was identified in OSCC samples.(77)  
Regarding the expression of CD44 in OSCC tissue samples, CD44 was 
detected in OSCC tissue samples by IHC analysis. It was also observed that 
CD44 was abundantly expressed in all OSCC samples tested (n=15) and 
therefore conform to data collected by most of the researchers.(78-87) 
The present study results demonstrated that the overexpression of the 
adhesion molecule CD44 had significantly higher association with the histological 
grade in OSCC.  Intense, moderate and weak expressions were associated with 
poorly, moderately and well differentiated histological grades respectively. Hence 
CD44 overexpression could be used in OSCC staging as; a sign of aggressiveness, 
a prognostic factor in OSCC and to assist in treatment. 
The current study results were in accordance with; Ghuwalewala et al (83) 
who found that CD44high CD24low cell population displayed increased CSC and 
EMT properties. They also showed high tumorigenic potential, drug resistance, 
invasion and metastasis. 
De Andrade et al (84) study showed that CD44high derived tumors were 
heterogeneous and showed differential expression pattern of CSC and EMT 
markers. According to Ohkoshi et al (85) the up regulation of CD44 serves as a 
survival mechanism, allowing cells to escape apoptosis in response to DNA 
damage repair in HNSCC. 
Baschnagel et al (86) concluded that High CD44 expression is associated with 
poor prognosis in HNSCC patients treated with chemo-radiation. Dunkelet al 
(87) immunohistochemistry of CD44 may be useful in identification of patients 
with poor prognoses. This may eventually aid in treatment planning.  
Kokko et al (78)  and  Kanke et al (80) who found that CD44 overexpression 
could be used as; a prognostic factor in HNSCC and as a sign of aggressiveness. 
Lindquist et al (79) observed that high intensity CD44 staining was 
correlated to poor. Chen et al (82) concluded that patients with lower CD44 
expression had a better survival prognosis.  
Maula et al (81) study concluded that CD44 may be a useful predictive and 
prognostic tool in the clinical management of HNSCC. 
Wang et al (56) reported that; different CD44 isoforms expressions were 
associated with HNSCC lymph node metastasis, advanced T status, perineural 
invasion, shorter survival, distant metastasis and failure of radiotherapy.  
In contrast to the current study results, Faber et al (88) found that the 
staining pattern shown in immunohistochemistry revealed a monotonic staining 
pattern of almost all cells except stromal and vascular cells. Similarly, Han et al 
(89) found that CD44 was abundantly expressed in all HNSCC samples tested. 
Prince et al (9) who first postulated CD44+ cells as CSCs reported that, 
CD44+ cancer cells typically comprise <10% of the cells in HNSCC tumor. A 
possible reason might be the different experimental methods of CD44 detection. 
However, the limitation of their study was that in two-thirds of the samples used, 
it was necessary to pass the cells initially in immunocompromised mice to have a 
sufficient number of tumor cells to isolate CSCs. This could have altered the 
expression patterns of native CSCs. 
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Pries et al (90) found that CD44+ CSCs may play a key role in the 
establishment of permanent HNSCC cell lines and might drive the progression 
and metastasis of HNSCC. 
The tumorigenicity of CD44+ cells of HNSCC seemed also to increase when 
such cells co-express additional markers such as the ALDH or CD24.(91, 92) 
Campos et al (91) observed that ALDH+ and CD44+ have higher proliferation 
rates and are more resistant to apoptosis than control cells (ALDH- CD44-). 
Though CD44 is generally accepted as a substitute marker for HNSCC CSCs.(9) 
In contrast to the present study results a recent study by Oh et al,(93)  reported 
that; CSCs themselves hold the ability to be heterogonous due to various genetic 
alterations. 
The discrepancy between Oh et al (93) results and the present study results 
may be explained as follows, CD44– HNSCC cells have stem cell trait due to 
three reasons. Firstly, brief culture can make tumor cell viability more stable 
because the procedure used itself is toxic to tumor cell. Secondly, the 
environment of an in vitro short-term culture may select for the CD44– HNSCC 
cells with CSC traits. Thirdly, a high proportion of cells in HNSCC may have the 
potential to drive cancer progression.  
Similarly, Bloor et al (94) found no evidence of association between CD44 
expression and prognostic significance. This may be due to the limited number of 
patients evaluated in the previous two studies. 
There are several possible explanations for these discrepant results. First of 
all, many of the previous studies used antibodies for specific variants of CD44. 
Although the expression of specific variants may be reduced in tumors with a 
worse prognosis while the overall CD44 expression may not. 
Second, CD44 was highly expressed on stromal and inflammatory cells, which 
were excluded on performing flow cytometric analysis. Although it is possible on 
histologic study to differentiate between tumor and non tumor cells, it may not 
be as accurate at excluding these cells. 
Third, different studies used different antibodies, making comparisons across 
reports from different research groups difficult. Certain CD44 variant domain 
epitopes might have been hidden and not recognized by some antibodies because 
of posttranslational changes that alter the three-dimensional conformation of the 
protein.  
Soluble CD44 was evaluated in blood serum of patients with different 
primary cancers, (95-99) as well as in oral rinses of patients with HNSCC. (100) 
Elevated CD44 serum levels have been found for several other tumor types using 
ELISA analysis.(97) The finding of high CD44sol levels in patients affected by 
cancer might be related to the amount of the extracellular fraction of the CD44 
antigen released by stem cells that remain on the tumor mass.(60, 101)  
In the present study, ELISA was used to evaluate the concentrations of 
CD44sol in patients with OSCC in relation to benign epithelial tumors patients 
and normal donors (healthy individuals). The results revealed a significant 
correlation at (P > 0.001) between serum CD44 concentration in patients with 
OSCC, patients with benign tumors patients and normal donors (healthy 
individuals).  
Serum CD44 levels were also correlated with tumor histological 
differentiation. There was a significant correlation at (P > 0.001) between serum 
CD44 concentrations in patients with different histological grades of OSCC. 
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Patients with poorly differentiated tumors had the highest concentration of 
CD44sol in their serum. 
These results were in accordance to the results found by Patel et al (101) 
who concluded that circulating tumor cells exhibit immense potential in 
enhancing diagnosis, prognosis and response to therapy in solid malignancies. 
Faber et al (88) found a significantly higher difference between concentration 
of CD44sol in serum of HNSCC patients in comparison to healthy controls. This 
accordance may be because they similarly measured the total quantity of CD44sol 
including all isoforms just as the present study. 
Kawano et al (65) concluded that there were significant differences in 
pretreatment median serum level of soluble CD44v5, CD44v6 and CD44st in the 
patient group and the control. They also found that the median post-treatment 
serum levels of CD445, CD44v6 and CD44vst were significantly lower than the 
pre-treatment levels. They also proposed that the determination of serum levels 
of CD44sol before treatment might be used to provide the clinician with 
important additional information for prognosis of patients with HNSCC. Their 
study confirmed that the serum CD44sol concentration might help guide the 
practitioner to select the appropriate therapy. 
Lin et al (102) revealed that the CD44sol levels in the peripheral blood of 
patients with locally advanced oral or oropharynx cancer were much higher than 
they were in healthy people. The pretreatment CD44sol levels of greater than 
fivefold were associated with the prognosis of the disease and the prediction of 
recurrence in patients who had received chemo-/radiotherapy. A high CD44sol 
level was significantly related to poor prognosis. 
Franazmann et al concluded in his studies (55, 66, 103) that, oral rinse 
CD44sol level appears to hold promise for early detection of HNSCC. The 
revealed data showed that the CD44sol test was very specific for HNSCC.  
Additionally, Periera et al (104) reported that the salivary CD44sol levels were 
much higher in HNSCC patients than in patients with benign disease. 
Similarly Chen et al (76) proposed that, detecting the CD44sol levels in oral 
rinses might be a good prognostic prediction. Among the advantages of oral rinses 
are their convenience and noninvasiveness. The present study measured the level 
of CD44sol in the peripheral blood, which is supposed to be more accurate. This 
may be because it omits the human factor and physiological variations that may 
alter the final results. 
The present study results were in contrast to the findings reported by Van 
Hal et al (96), who did not find significant differences between the CD44v6 
plasma levels in HNSCC patients and control groups. A reason might be the 
measurement of different isoforms of CD44. In the present study all standard and 
variant isoforms were measured. An explanation for the findings of Van Hal et al 
might be given by Herold-Mende et al (105) who concluded that the expression of 
CD44v5 and CD44v6 was unaltered in HNSCC patients. 
Also in contrast to the present study results, Franzmann et al (103) found 
that the plasma level of CD44sol was not significantly different between oral 
cancer patients and normal controls. This might be attributed to the relative 
small burden of oral tumors that may not alter the basal level of CD44sol. 
In accordance to the present study results, in laryngeal carcinomas, the high 
expression of CD44 appears to correlate with poor prognosis because of regional 
or distant metastasis and radiotherapy resistance.(60, 106) Allegra et al (60) 
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concluded that the determination of CD44sol levels as a potential diagnostic 
marker of laryngeal cancer in the saliva of patients with laryngeal carcinoma 
using ELISA seems to be a promising method. 
For other types of cancer CD44v6 has already been shown to be a potential 
marker of prognosis. Saito et al (95) postulated that the serum concentration of 
CD44v6 and its expression in tumors were associated significantly with the depth 
of invasion of the tumor, lymph node metastasis and clinical stage in patients 
with diffuse type gastric carcinoma. He also found that there was a significant 
correlation to the stage of primary tumor expansion, lymph node metastasis or 
distant metastasis. 
Guo et al (62) concluded that there was a significant correlation between 
serum CD44 concentration in patients with metastatic colon cancer and serum 
CD44 concentration in normal donors. Elevated serum CD44 levels in these 
patients may be due to active shedding of CD44 molecules by the tumor cells. In 
contrast to Lein et al (107) who found no increase in the standard and variant 
CD44 proteins in the serum of patients with urological malignancies (prostate 
cancer, renal cell cancer or bladder cancer). 
In the present study the analysis of the malignant cells invasion into the 
surrounding structures in relation to the concentrations of CD44sol in serum 
revealed significant difference.  
Several other studies postulated that; CD44sol was identified in serum, 
plasma or urine of patients with different tumors. Serum level of CD44sol was 
correlated with tumor progression in a wide variety of human malignancies.(62, 
95, 108) 
In contrast to the current study results, Faber et al (88) found that there was 
no correlation between concentration of CD44sol in serum of HNSCC patients 
and the tumor invasion. 
In the present work the analysis of the clinical data in relation to the 
concentrations of CD44sol in serum revealed an absence of significant differences 
between the histological grades according to tumor site and tumor size. These 
results were in accordance to Kawano et al (65) who found that there was no 
significant correlation between the serum levels of soluble CD44v5, CD44v6 and 
CD44st and the clinicopathological variables. 
The determination of CD44sol levels in the serum of patients with OSCC 
using ELISA, compared with other screening tests as PSA for prostate cancer 
(109) and the Pap test for cervical cancer,(110) seems to be a promising 
diagnostic test in terms of high sensitivity and specificity, low cost and 
noninvasiveness of the technique. 
 
 
Conclusions 
 
Based on the present study results, the following conclusions were obtained: 
1. Cancer stem cells can be reliably detected immunohistochemically in fixed 
human tissues of OSCC and in all the control specimens. 
2. CD44 marker can be used to identify specific subpopulations of CSCs that 
are resistant to therapy and require more aggressive treatment strategies. 
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3. The pattern of CD44 immunosignals was expressed in the cell membrane of 
all OSCC cases studied.  
4. Computer based image analysis showed that there was a significant difference 
between mean optical density and mean area percent of CD44 expression in 
different grades of OSCC cases as well as control cases. 
5. A directly proportional relation was present between CD44sol value in 
peripheral blood of OSCC patients evaluated using ELISA and the amount of 
CSCs detected by immunohistochemistry (CD44) in fixed human tissues of 
OSCC. 
6. CD44 expression level either in the soluble form or in the cell membrane was 
associated with tumor aggressiveness and invasion indicating the importance 
of this molecule in progression of OSCC.  
7. CD44 detection in OSCC tissue and determination of CD44sol levels in the 
serum of patients with OSCC using ELISA seemed to have a potential 
prognostic and predictive value in the management of OSCC.  
8. The serum level of CD44sol might be a useful marker for tumor screening. 
 
 
Recommendations 
 
1. Further studies with longer follow-up and a larger number of patients are 
needed. 
2. Further studies should be done to evaluate the therapeutic implications of 
CD44 in cancer treatment. 
3. Further studies should be done to evaluate effectiveness of CD44 marker in 
detecting occult carcinomas. 
4. Peripheral CD44sol level evaluation is recommended to provide presurgical 
information about the primary tumor grade and regional extension. 
5. CD44sol detection using ELISA could potentially be used in community 
outreach programs, since sample collection and its laboratory processing are 
so simple. 
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